Dystrophin deficiency impairs cell junction formation during embryonic myogenesis.
Elise MozinEmmanuelle MassouridesVirginie MournetasClémence LièvreAudrey BourdonDana L JacksonJonathan S PackerCole TrapnellCaroline Le GuinerOumeya AdjaliChristian PinsetDavid L MackJean-Baptiste DupontPublished in: bioRxiv : the preprint server for biology (2023)
Mutations in the DMD gene lead to Duchenne muscular dystrophy, a severe X-linked neuromuscular disorder which manifests itself as young boys acquire motor functions. DMD is diagnosed after 2 to 4 years, but the absence of dystrophin has an impact before symptoms appear in patients, which poses a serious challenge in the optimization of standards of care. In this report, we investigated the early consequences of dystrophin deficiency during skeletal muscle development. We used single-cell transcriptome profiling to characterize the myogenic trajectory of human pluripotent stem cells and showed that DMD cells bifurcate to an alternative branch when they reach the somite stage. Here, dystrophin deficiency was linked to marked dysregulations of cell junction families involved in the cell state transitions characteristic of somitogenesis. Altogether, this work demonstrates that in vitro , dystrophin deficiency has early consequences during myogenic development, which should be considered in future therapeutic strategies for DMD.
Keyphrases
- duchenne muscular dystrophy
- single cell
- skeletal muscle
- rna seq
- muscular dystrophy
- pluripotent stem cells
- end stage renal disease
- cell therapy
- endothelial cells
- replacement therapy
- healthcare
- high throughput
- chronic kidney disease
- gene expression
- induced apoptosis
- type diabetes
- newly diagnosed
- cell cycle arrest
- insulin resistance
- cell death
- palliative care
- mesenchymal stem cells
- bone marrow
- metabolic syndrome
- current status
- peritoneal dialysis
- chronic pain
- endoplasmic reticulum stress
- pi k akt
- genome wide identification
- affordable care act